Is Merck stock a Buy, Sell or Hold?
Merck stock has received a consensus rating of buy. The average rating score is A1 and is based on 46 buy ratings, 18 hold ratings, and 0 sell ratings.What was the 52-week low for Merck stock?
The low in the last 52 weeks of Merck stock was 78.65. According to the current price, Merck is 132.36% away from the 52-week low.What was the 52-week high for Merck stock?
The high in the last 52 weeks of Merck stock was 115.48. According to the current price, Merck is 90.15% away from the 52-week high.What are analysts forecasts for Merck stock?
The 64 analysts offering price forecasts for Merck have a median target of 104.84, with a high estimate of 135.00 and a low estimate of 70.00. The median estimate represents a 99.29 difference from the last price of 104.10.Merck Stock Snapshot
104.19
Bid
7,500.00
Bid Size
104.20
Ask
37,800.00
Ask Size
3/17/2023
Date
4:15 PM
Time
15.29 M
Volume
107.34
Prev. Close
107.19
Open
273.36 B
Market Cap
2.54 B
Number of Shares
103.49
Day Low
107.31
Day High
104.10
78.65
52 Week Low
115.48
52 Week High
104.10
2.95
Dividend
2.77
Dividend Yield
14.94
P/E Ratio
99.88
Free Float in %
6.90
EPS 2023
7.86
Cash Flow per Share
Merck News More News
Historical Prices for Merck
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Merck Analyst Data
Total Analysts: 64
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 70.00
Median: 104.84
Highest: 135.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Merck Analyst Opinions
- All
- Buy
- Hold
- Sell
| 03/17/23 | Mizuho | Maintained Buy | $130 | ||
| 03/13/23 | Wells Fargo & Co | Downgraded to Hold | $115 | ||
| 03/10/23 | Berenberg | Maintained Buy | $130 | ||
| 03/07/23 | Credit Suisse | Maintained Buy | $126 | ||
| 03/07/23 | Atlantic Equities | Maintained Buy | $127 | ||
| 03/06/23 | Jefferies & Company Inc. | Maintained Buy | $125 | ||
| 02/23/23 | J.P. Morgan | Maintained Buy | $125 | ||
| 02/22/23 | Wolfe Research | Upgraded to Buy | $127 | ||
| 02/13/23 | Credit Suisse | Maintained Buy | $125 | ||
| 02/03/23 | Wells Fargo & Co | Maintained Buy | $120 | ||
| 02/03/23 | Morgan Stanley | Maintained Hold | $99 | ||
| 02/03/23 | SVB Leerink | Maintained Buy | $122 | ||
| 01/23/23 | SVB Leerink | Maintained Buy | $120 | ||
| 01/04/23 | Bank of America Merrill Lynch | Upgraded to Buy | $130 | ||
| 01/03/23 | Wells Fargo & Co | Maintained Buy | $125 | ||
| 12/19/22 | Cantor Fitzgerald | Maintained Buy | $135 | ||
| 11/18/22 | Credit Suisse | Maintained Buy | $120 | ||
| 11/01/22 | Guggenheim | Maintained Buy | $111 | ||
| 10/28/22 | Barclays Capital | Maintained Buy | $110 | ||
| 10/28/22 | Morgan Stanley | Maintained Hold | $100 | ||
| 10/28/22 | Wells Fargo & Co | Maintained Buy | $110 | ||
| 10/28/22 | SVB Leerink | Maintained Buy | $112 | ||
| 10/28/22 | Atlantic Equities | Maintained Buy | $122 | ||
| 10/12/22 | Morgan Stanley | Maintained Hold | $91 | ||
| 10/11/22 | Atlantic Equities | Maintained Buy | $116 | ||
| 10/10/22 | Guggenheim | Upgraded to Buy | |||
| 09/30/22 | SVB Leerink | Maintained Buy | $110 | ||
| 09/14/22 | Berenberg | Upgraded to Buy | $100 | ||
| 09/12/22 | SVB Leerink | Maintained Buy | $109 | ||
| 07/29/22 | Barclays Capital | Maintained Buy | $101 | ||
| 07/29/22 | Morgan Stanley | Maintained Hold | $92 | ||
| 07/29/22 | SVB Leerink | Maintained Buy | $105 | ||
| 07/18/22 | UBS | Maintained Hold | $98 | ||
| 07/13/22 | Atlantic Equities | Maintained Buy | $110 | ||
| 07/08/22 | Morgan Stanley | Maintained Hold | $88 | ||
| 07/07/22 | Daiwa Securities | Upgraded to Buy | $102 | ||
| 06/27/22 | Cowen and Company, LLC | Maintained Hold | $102 | ||
| 04/29/22 | Morgan Stanley | Maintained Hold | $87 | ||
| 04/29/22 | Wells Fargo & Co | Maintained Buy | $105 | ||
| 04/29/22 | SVB Leerink | Maintained Buy | $102 | ||
| 04/21/22 | SVB Leerink | Maintained Buy | $97 | ||
| 04/12/22 | Barclays Capital | Maintained Buy | $97 | ||
| 04/06/22 | Morgan Stanley | Maintained Hold | $80 | ||
| 04/06/22 | SVB Leerink | Maintained Buy | $100 | ||
| 02/04/22 | SVB Leerink | Maintained Buy | $101 | ||
| 01/28/22 | J.P. Morgan | Maintained Buy | $95 | ||
| 12/16/21 | Daiwa Securities | Maintained Hold | $70 | ||
| 12/13/21 | UBS | Downgraded to Hold | $76 | ||
| 12/09/21 | Wells Fargo & Co | Maintained Buy | $90 | ||
| 12/07/21 | Guggenheim | Downgraded to Hold |
Merck Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 58,100 | 61,639 | 65,037 | 68,399 | 71,246 |
| Dividend | 2.95 | 3.24 | 3.48 | 3.91 | 4.11 |
| Dividend Yield (in %) | 2.77 % | 3.03 % | 3.26 % | 3.66 % | 3.85 % |
| EPS | 6.90 | 8.55 | 9.53 | 10.14 | 11.08 |
| P/E Ratio | 15.22 | 12.27 | 11.01 | 10.36 | 9.48 |
| EBIT | 21,226 | 25,829 | 28,467 | 30,110 | 32,391 |
| EBITDA | 24,224 | 28,948 | 31,519 | 33,116 | 35,137 |
| Net Profit | 17,559 | 21,541 | 23,829 | 25,369 | 27,380 |
| Net Profit Adjusted | 17,559 | 21,670 | 24,003 | 25,369 | 27,380 |
| Pre-Tax Profit | 21,168 | 25,477 | 28,320 | 30,064 | 32,644 |
| Net Profit (Adjusted) | 19,766 | 24,095 | 27,521 | 28,463 | 29,864 |
| EPS (Non-GAAP) ex. SOE | 6.90 | 8.55 | 9.53 | 10.14 | 11.08 |
| EPS (GAAP) | 6.34 | 8.15 | 9.17 | 9.65 | 10.52 |
| Gross Income | 44,268 | 48,176 | 51,419 | 53,592 | 56,532 |
| Cash Flow from Investing | -4,539 | -4,424 | -4,458 | -5,191 | -5,184 |
| Cash Flow from Operations | 20,880 | 23,479 | 26,360 | 27,897 | 29,976 |
| Cash Flow from Financing | -9,205 | -10,870 | -12,154 | -12,819 | -13,394 |
| Cash Flow per Share | 7.86 | 9.38 | 10.37 | 11.69 | - |
| Free Cash Flow | 16,800 | 20,166 | 23,388 | 21,542 | 25,137 |
| Free Cash Flow per Share | 6.00 | 9.47 | 10.78 | 10.58 | - |
| Book Value per Share | - | - | - | 31.62 | 32.01 |
| Net Debt | 7,355 | -1,655 | -13,313 | -16,302 | -23,941 |
| Research & Development Exp. | 13,016 | 12,424 | 12,882 | 13,287 | 13,621 |
| Capital Expenditure | 3,410 | 3,349 | 3,400 | 3,433 | 3,521 |
| Selling, General & Admin. Exp. | 10,279 | 10,516 | 10,899 | 11,266 | 11,561 |
| Shareholder’s Equity | 54,855 | 65,028 | 77,376 | 91,995 | 106,911 |
| Total Assets | 120,778 | 129,345 | 140,297 | 155,209 | 170,962 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 19 | 18 | 18 | 21 | 21 |
| Average Estimate | 1.535 USD | 1.366 USD | 1.781 USD | 6.900 USD | 8.555 USD |
| Year Ago | 1.800 USD | 2.140 USD | 1.870 USD | 7.480 USD | 6.900 USD |
| Publish Date | 2/2/2023 | 4/27/2023 | 8/1/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 16 | 16 | 15 | 20 | 20 |
| Average Estimate | 13,658 USD | 13,806 USD | 14,193 USD | 58,100 USD | 61,639 USD |
| Year Ago | 13,521 USD | 15,901 USD | 14,593 USD | 59,283 USD | 58,100 USD |
| Publish Date | 2/2/2023 | 4/27/2023 | 8/1/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Merck Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Romanelli Joseph | 02/14/2023 | 5,000.00 | 20,284.33 | 108.22 | Sell | No |
| MIZELL STEVEN | 02/12/2023 | 1,815.00 | 33,085.15 | 109.10 | Sell | No |
| Williams David Michael | 02/09/2023 | 413.00 | 12,091.89 | 106.72 | Sell | No |
| Williams David Michael | 02/09/2023 | 1,205.00 | 12,504.89 | 106.72 | Buy | No |
| MIZELL STEVEN | 02/08/2023 | 5,000.00 | 34,900.15 | 107.00 | Sell | No |
| MIZELL STEVEN | 02/05/2023 | 4,436.00 | 39,900.15 | 104.25 | Sell | No |
| Zachary Jennifer | 02/02/2023 | 75,436.00 | 53,919.94 | 103.17 | Sell | No |
| Zachary Jennifer | 02/02/2023 | 75,436.00 | 129,355.94 | 56.04 | Buy | No |
| Williams David Michael | 01/22/2023 | 1,745.00 | 11,007.76 | 109.88 | Buy | No |
| Karachun Rita A | 01/22/2023 | 2,846.00 | 43,948.97 | 109.88 | Buy | No |
| MIZELL STEVEN | 01/22/2023 | 12,192.00 | 44,336.15 | 109.88 | Buy | No |
| Oosthuizen Johannes Jacobus | 01/22/2023 | 2,091.00 | 18,821.88 | 109.88 | Buy | No |
| Zachary Jennifer | 01/22/2023 | 15,631.00 | 53,919.94 | 109.88 | Buy | No |
| Li Dean Y | 01/22/2023 | 3,275.00 | 19,933.43 | 109.88 | Buy | No |
| Davis Robert M | 01/22/2023 | 24,224.00 | 271,816.76 | 109.88 | Buy | No |
| DeLuca Richard R. | 01/22/2023 | 15,628.00 | 153,500.38 | 109.88 | Buy | No |
| Klobuchar Michael A | 01/22/2023 | 2,651.00 | 17,989.93 | 109.88 | Buy | No |
| Chattopadhyay Sanat | 01/22/2023 | 17,495.00 | 46,995.00 | 109.88 | Buy | No |
| Litchfield Caroline | 01/22/2023 | 2,656.00 | 30,186.68 | 109.88 | Buy | No |
| Chattopadhyay Sanat | 01/08/2023 | 1,702.00 | 29,500.00 | 114.46 | Sell | No |
| Chattopadhyay Sanat | 01/08/2023 | 38,216.00 | 31,202.00 | 113.78 | Sell | No |
| Chattopadhyay Sanat | 01/08/2023 | 3,940.00 | 69,418.00 | 112.78 | Sell | No |
| Chattopadhyay Sanat | 01/08/2023 | 4,538.00 | 73,358.00 | 111.73 | Sell | No |
| Chattopadhyay Sanat | 01/08/2023 | 35,598.00 | 77,896.00 | 110.61 | Sell | No |
| Chattopadhyay Sanat | 01/08/2023 | 83,994.00 | 113,494.00 | 53.06 | Buy | No |
Merck Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Merck Co. | 2.80 | 2.52 | USD |
| 2021 | Merck Co. | 2.64 | 3.44 | USD |
| 2020 | Merck Co. | 2.48 | 3.03 | USD |
| 2019 | Merck Co. | 2.26 | 2.48 | USD |
| 2018 | Merck Co. | 1.99 | 2.60 | USD |
| 2017 | Merck Co. | 1.89 | 3.36 | USD |
| 2016 | Merck Co. | 1.85 | 3.14 | USD |
| 2015 | Merck Co. | 1.81 | 3.43 | USD |
| 2014 | Merck Co. | 1.77 | 3.12 | USD |
| 2013 | Merck Co. | 1.73 | 3.46 | USD |
| 2012 | Merck Co. | 1.68 | 4.10 | USD |
| 2012 | Merck Co. | 1.69 | 4.13 | USD |
| 2011 | Merck Co. | 1.52 | 4.03 | USD |
| 2011 | Merck Co. | 1.56 | 4.14 | USD |
| 2010 | Merck Co. | 1.52 | 4.22 | USD |
| 2009 | Merck Co. | 1.52 | 4.16 | USD |
| 2008 | Merck Co. | 1.52 | 5.00 | USD |
| 2007 | Merck Co. | 1.52 | 2.62 | USD |
| 2006 | Merck Co. | 1.52 | 3.49 | USD |
| 2005 | Merck Co. | 1.52 | 4.78 | USD |
| 2004 | Merck Co. | 1.49 | 4.64 | USD |
| 2003 | Merck Co. | 1.45 | 3.14 | USD |
| 2002 | Merck Co. | 1.41 | 2.49 | USD |
| 2001 | Merck Co. | 1.37 | 2.33 | USD |
| 2000 | Merck Co. | 1.21 | 1.29 | USD |
| 1999 | Merck Co. | 1.12 | 1.67 | USD |
*Yield of the Respective Date
Merck Co. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.366 USD | Q1 2023 Earnings Release | 04/27/2023 |
| Press Conference | - | 04/27/2023 | |
| Earnings Report | 1.781 USD | Q2 2023 Earnings Release | 08/01/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/26/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 02/01/2024 |
| Earnings Report | - | Q1 2024 Earnings Release | 04/30/2024 |
| Earnings Report | - | Q2 2024 Earnings Release | 07/26/2024 |
| Earnings Report | - | Q3 2024 Earnings Release | 10/24/2024 |
Merck Co. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 1.620 USD | Q4 2022 Earnings Release | 02/02/2023 |
| Press Conference | - | - | 10/27/2022 |
| Shareholders' Meeting | - | - | 05/24/2022 |
Merck Profile
Merck & Co. , Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Moody’s Daily Credit Risk Score
Merck Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.88 |
| Vanguard Group, Inc. (Subfiler) | 8.53 |
| State Street Corp. | 4.65 |
| BlackRock Fund Advisors | 3.23 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| Wellington Management Co. LLP | 2.45 |
| Vanguard 500 Index Fund | 2.32 |
| BlackRock Institutional Trust Co. NA | 2.24 |
| Geode Capital Management LLC | 1.91 |
| Charles Schwab Investment Management, Inc. | 1.18 |
| Fidelity 500 Index Fund | 1.09 |
| SPDR S&P 500 ETF Trust | 1.08 |
| T. Rowe Price Associates, Inc. (Investment Management) | 1.04 |
| Norges Bank (13F) | 0.97 |
| Government Pension Fund - Global (The) | 0.95 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Merck Management
| Name | Job |
|---|---|
| James Matteucci | Associate Director-State Government Affairs |
| Robert M. Davis | Chairman, President & Chief Executive Officer |
| Caroline A. Litchfield | Chief Financial Officer & Executive Vice President |
| Steven C. Mizell | Chief Human Resources Officer & Executive VP |
| Dave Williams | Chief Information & Digital Officer |
| Chirfi Guindo | Chief Marketing Officer-Human Health & SVP |
| Michael Klobuchar | Chief Strategy Officer & Executive Vice President |
| Sanat Chattopadhyay | EVP & President-Merck Manufacturing Division |
| Dean Y. Li | EVP & President-Merck Research Laboratories |
| Brooke Hinkson | Executive Director-Global Clinical Data Standards |
| Jennifer Zachary | Executive Vice President & General Counsel |
| Richard R. DeLuca | Executive Vice President & President-Animal Health |
| Stephen L. Mayo | Independent Director |
| Douglas M. Baker | Independent Director |
| Risa J. Lavizzo-Mourey | Independent Director |
| Peter C. Wendell | Independent Director |
| Mary Ellen Coe | Independent Director |
| Kathy J. Warden | Independent Director |
| Inge G. Thulin | Independent Director |
| Christine E. Seidman | Independent Director |
| Pamela J. Craig | Independent Director |
| Patricia Fiorello Russo | Independent Director |
| Paul B. Rothman | Independent Director |
| Thomas Henry Glocer | Lead Independent Director |
| Sylvia A. Ayler | Legal Director |
| Carol Bowden | Med Aff. Dir, Cardiovascular Metabolism, NorCal |
| Allan Gabor | President-Asian-Pacific-BioPharma Business |
| Joseph Romanelli | President-Human Health International |
| Jannie Oosthuizen | President-Merck Human Health |
| Andre Musto | SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
| Kelly E. W. Grez | Secretary |
| Fiona Hamilton Marshall | Senior VP & Global Head-Discovery Sciences |
| Lisa LeCointe-Cephas | Senior VP, Chief Ethics & Compliance Officer |
| Eric H. Rubin | Senior VP-Global Clinical Oncology |
| Rita A. Karachun | Senior Vice President-Finance & Global Controller |
| Jacks Lee | Senior Vice President-Manufacturing & Supply |
| Denise Williams | Vice President |
| Johanna Herrmann | Vice President-Global Communications |
| Peter Dannenbaum | Vice President-Investor Relations |